Enveric Biosciences (ENVB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENVB Enveric Biosciences

Watchlist

0.3223
-0.0047-1.44%

Trading Nov 27 10:12 ET

3.21MMarket Cap-133P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enveric Biosciences Completes PK EB-003 Studies
TipRanksNov 25 09:05 ET
Express News | Enveric Biosciences : Plans to Submit Eb-003 Ind Application to FDA in H2 of 2025
ReutersNov 25 09:02 ET
Express News | Enveric Biosciences Preclinical Pharmacokinetic Studies of Eb-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior
ReutersNov 25 09:01 ET
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
BenzingaNov 25 09:00 ET
Express News | Enveric Biosciences Inc: On Nov 20, Nasdaq Issued Delisting Notice on Failing to Meet Minimum Bid Price Requirement
ReutersNov 22 16:47 ET
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
BenzingaNov 19 06:30 ET

Comments

Jaguar8

Nov 25 08:04

NEWS

$Enveric Biosciences (ENVB.US)$
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant brain penetration was observed in rat
Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enver...

Trytosaveabit

Nov 25 08:03

Update

$Enveric Biosciences (ENVB.US)$ Reuters· 1 min ago
Enveric Biosciences Preclinical Pharmacokinetic Studies of Eb-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

dSuu

Nov 21 07:50

$Enveric Biosciences (ENVB.US)$ whoaaaaaa

Jaguar8

Nov 12 08:09

NEWS

$Enveric Biosciences (ENVB.US)$
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences (NASDAQ: ENVB)has signed a licensing agreement with MycoMedica Life Sciences for its EVM201 program, including drug candidate EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The agreement includes potential milestone payments up to $62 million plus tiered single-digit royalties on future sales. MycoMedica receives exclusive globa...